文章基本信息

标题：Efficacy and safety of darunavir (Prezista®) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study
本地全文：下载
作者：Otilia Elisabeta Benea ; Adrian Streinu-Cercel ; Carmen Dorobăț 等
期刊名称：Germs
印刷版ISSN：2248-2997
出版年度：2014
卷号：4
期号：3
页码：59-69
DOI：10.11599/germs.2014.1057
出版社：European HIV/AIDS and Infectious Diseases Academy
摘要：Introduction The aim of the study was to assess the safety and efficacy of darunavir (Prezista®)used in subtype F human immunodeficiency virus – type 1 (HIV-1) infected, antiretroviral therapy (ART)-experienced patients in Romania in routine clinical practice. Methods This was a post-authorization, open-label, one-cohort, non-interventional, prospective study conducted at multiple sites in Romania to assess efficacy (CD4 cell count, viral load, and treatment compliance) and safety ([serious] adverse events, clinical laboratory evaluation, and vital signs) of darunavir in combination with low-dose ritonavir (DRV/r) and other antiretroviral (ARV) medications in subtype F HIV-1 infected subjects in naturalistic settings. Seventy-eight subjects were recruited by 9investigational sites and received 600/100mg DRV/r twice daily.Results Treatment with DRV/r administered with other ARV medications resulted in the expected, statistically relevant improvement of CD4 cell count and viral load in subjects eligible for such treatment. In addition, adherence to treatment was high and the treatment‑emergent safety profile observed during this study was consistent with the established safety profile of darunavir.Conclusion DRV/r administered in combination with other ARV medications in subtype F HIV-1 infected subjects in naturalistic settings proved to be an effective and safe treatment in Romania.
关键词：Darunavir; ritonavir; antiretroviral therapy; HIV-1; safety; efficacy; prospective study